Preparation method of polyhydroxyalkanoate

By obtaining the suspension of PHA-containing cells and performing solid-liquid separation, deep concentration and non-halogen organic solvent extraction, combined with alkaline treatment and ultrasonic treatment, the problems of low separation efficiency and high energy consumption in the production of polyhydroxy fatty acid ester are solved. It realizes efficient extraction of high-purity PHA.

CN118909237APending Publication Date: 2024-11-08SINGULARITY NEW MATERIAL TECHNOLOGY (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410583472.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing polyhydroxy fatty acid ester production technology has problems such as low separation efficiency, high energy consumption, high operation difficulty and limited separation capability.

Method used

By obtaining the PHA-containing cell suspension, performing solid-liquid separation and deep concentration, extraction using a non-halogen organic solvent, combined with alkaline treatment and ultrasonic treatment, a high-purity polyhydroxy fatty acid ester is formed.

Benefits of technology

It improves separation efficiency, reduces energy consumption, simplifies operation, and realizes separation and extraction of high-purity PHA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004834774620000011
    Figure HDA0004834774620000011
  • Figure HDA0004834774620000012
    Figure HDA0004834774620000012
  • Figure HDA0004834774620000021
    Figure HDA0004834774620000021
Patent Text Reader

Abstract

The embodiment of the invention relates to the field of polyhydroxyalkanoate preparation, and discloses a polyhydroxyalkanoate preparation method which comprises the following steps: obtaining a cell suspension containing PHA (polyhydroxyalkanoate); carrying out solid-liquid separation treatment on the turbid liquid containing the PHA cells, and collecting a primary concentrate; carrying out deep concentration on the primary concentrate, and collecting a secondary concentrate; the intracellular PHA in the secondary concentrate is extracted using a non-halogen organic solvent. According to the embodiment of the invention, the cell suspension containing PHA is subjected to precipitation, photo-thermal evaporation and solvent extraction treatment, PHA and other cytoplasm can be separated, high-purity PHA is obtained, the overall operation is simple, recyclable solar energy is utilized, the separation efficiency is improved, and the energy consumption is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The disclosed embodiments relate to the technical field of polyhydroxyalkanoate preparation, and more particularly to a method for preparing polyhydroxyalkanoate. Background Art

[0002] Polyhydroxyalkanoate (PHA) is an environmentally and bio-friendly intracellular polyester material with biodegradability and good biocompatibility. Currently, large-scale industrial production of PHA is usually prepared by fermentation. For example, Chinese patent CN111500650B discloses a method for efficiently producing PHA, comprising the steps of: inoculating PHA fermentation strains into a fermentation medium for fermentation under conditions capable of producing PHA by fermentation to obtain a fermentation broth; subjecting the fermentation broth to a first solid-liquid separation to obtain a fermentation clear liquid and a bacterial precipitate; breaking the bacterial precipitate, and subjecting the obtained broken wall product to plate-frame filtration to obtain the PHA. In addition, Chinese patent CN115807044A discloses a method for efficiently extracting and purifying high-purity polyhydroxyalkanoates, and the specific steps are as follows: (1) providing a bacterial suspension of PHA-producing bacteria, adding a surfactant, a protease or a lysozyme to break the bacterial wall, and collecting a crude PHA product; (2) extracting the crude PHA product with an organic solvent A, collecting the extract, removing the solvent, and preparing a product a1; dissolving the product a1 with an organic solvent A, adding an organic solvent B to the resulting solution for displacement, removing the displacement liquid, collecting a product a2, removing the solvent, and preparing a product a3; dissolving the product a3 with an organic solvent A, collecting the solution, removing the solvent, and extracting to obtain polyhydroxyalkanoates.

[0003] However, existing conventional PHA production technology has the following problems: low separation efficiency, high energy consumption, difficult operation, and limited separation capacity. Summary of the invention

[0004] The embodiments of the present disclosure provide a method for preparing polyhydroxyalkanoate to solve or alleviate one or more of the above technical problems in the prior art.

[0005] According to one aspect of the present disclosure, a method for preparing a polyhydroxyalkanoate is provided, comprising:

[0006] Obtain a cell suspension containing PHA;

[0007] Performing solid-liquid separation on the PHA cell suspension to collect a primary concentrate;

[0008] Deeply concentrating the primary concentrate to collect a secondary concentrate;

[0009] The intracellular PHA in the secondary concentrate was extracted using a non-halogen organic solvent.

[0010] In a possible implementation, obtaining the PHA cell suspension includes:

[0011] Collecting excess activated sludge from a municipal sewage treatment plant, wherein the excess activated sludge includes ordinary activated sludge, aerobic granular sludge or anaerobic granular sludge;

[0012] The remaining activated sludge is subjected to alkaline treatment to obtain an alkaline treatment solution;

[0013] The alkaline treatment solution is subjected to ultrasonic treatment to form a PHA-containing cell suspension.

[0014] In a possible implementation, the PHA cell suspension can also be extracted from industrial wastewater.

[0015] In a possible implementation, the intact cells (containing PHA) may be directly concentrated by precipitation without cell disruption, and the subsequent solvent extraction can simultaneously achieve the effect of cell disruption.

[0016] In a possible implementation, the solid-liquid separation treatment is performed on the PHA cell suspension to collect the primary concentrate, which includes:

[0017] A solid-liquid separation device is used to perform solid-liquid separation on the PHA cell suspension, and the solid-liquid separation device includes a centrifuge, a sedimentation tank or a membrane separation device.

[0018] In a possible implementation, the first-level concentrate is deeply concentrated, and collecting the second-level concentrate includes:

[0019] The primary concentrate is subjected to photothermal evaporation treatment using solar thermal energy, so that the water-soluble solvent in the primary concentrate is evaporated to obtain the residual secondary concentrate.

[0020] In one possible implementation, extracting intracellular PHA in the secondary concentrate using a non-halogen organic solvent includes: transmitting residual solar heat after photothermal evaporation of the primary concentrate to an extraction device to extract the intracellular PHA in the secondary concentrate.

[0021] In a possible implementation, the alkaline treatment of the excess activated sludge to obtain an alkaline treatment solution comprises:

[0022] Add 35% NaOH to the remaining activated sludge, adjust the pH to 11, the temperature to 45°C, and keep stirring for 1-2 hours.

[0023] In a possible implementation, ultrasonically treating the alkaline treatment solution to form a PHA cell suspension includes:

[0024] Stirring at a stirring speed of 500 to 1500 revolutions per minute for 3 to 8 hours;

[0025] Use an ultrasonic crushing device to perform ultrasonic treatment for 60 to 120 minutes while stirring at an output power of 200 to 800 W.

[0026] In a possible implementation, the concentration of excess activated sludge in the urban sewage treatment plant is 5 to 15 g.L-1.

[0027] According to one aspect of the present disclosure, a polyhydroxyalkanoate is provided, wherein the polyhydroxyalkanoate is prepared by the polyhydroxyalkanoate preparation method.

[0028] According to one aspect of the present disclosure, there is provided a use of a polyhydroxyalkanoate in the production of cosmetics and / or pharmaceutical products.

[0029] The exemplary embodiments of the present disclosure have the following beneficial effects: the exemplary embodiments of the present disclosure perform precipitation, photothermal evaporation, and solvent extraction on a PHA-containing cell suspension to separate PHA from other cytoplasm and obtain high-purity PHA. The overall operation is simple. This embodiment utilizes recyclable solar energy to improve separation efficiency and reduce energy consumption.

[0030] The details of one or more embodiments of the present application are presented in the following drawings and descriptions. Other features and advantages of the present application will become apparent from the accompanying drawings. It should be understood that the above general description and the detailed descriptions below are only exemplary and explanatory and cannot limit the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The accompanying drawings herein are incorporated into the specification and constitute a part of the specification, illustrate embodiments consistent with the present disclosure, and together with the specification are used to explain the principles of the present disclosure. Obviously, the accompanying drawings described below are only some embodiments of the present disclosure, and for ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without creative work.

[0032] Figure 1 is one of the flow charts of a method for preparing polyhydroxyalkanoate of this exemplary embodiment;

[0033] Figure 2 This is a flow chart of the second method for preparing polyhydroxyalkanoate of this exemplary embodiment; Figure 3 This is the third flow chart of a method for preparing polyhydroxyalkanoate according to this exemplary embodiment. DETAILED DESCRIPTION

[0034] Example embodiments will now be described more fully with reference to the accompanying drawings. However, example embodiments can be implemented in a variety of forms and should not be construed as being limited to the examples set forth herein; on the contrary, these embodiments are provided so that the present disclosure will be more comprehensive and complete, and the concepts of the example embodiments are fully conveyed to those skilled in the art. The described features, structures, or characteristics may be combined in one or more embodiments in any suitable manner. In the following description, many specific details are provided to provide a full understanding of the embodiments of the present disclosure. However, those skilled in the art will appreciate that the technical solutions of the present disclosure may be practiced while omitting one or more of the specific details, or other methods, components, devices, steps, etc. may be adopted. In other cases, known technical solutions are not shown or described in detail to avoid obscuring various aspects of the present disclosure.

[0035] In addition, the accompanying drawings are only schematic illustrations of the present disclosure and are not necessarily drawn to scale. The same reference numerals in the figures represent the same or similar parts, and thus their repeated description will be omitted. Some of the block diagrams shown in the accompanying drawings are functional entities and do not necessarily correspond to physically or logically independent entities. These functional entities can be implemented in software form, or implemented in one or more hardware units or integrated circuits, or implemented in different networks and / or processor devices and / or microcontroller devices.

[0036] The flowcharts shown in the accompanying drawings are only exemplary and do not necessarily include all the steps. For example, some steps may be decomposed, while some steps may be combined or partially combined, so the actual execution order may change according to the actual situation.

[0037] The terms "first", "second", etc. in the specification and claims of the present application and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the terms used in this way can be interchanged where appropriate, so that the embodiments of the present application described herein can be implemented in an order other than those illustrated or described herein, for example.

[0038] In addition, the terms "include" and "have" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product, or apparatus comprising a series of steps or sub-modules is not necessarily limited to those steps or sub-modules explicitly listed, but may include other steps or sub-modules not explicitly listed or inherent to these processes, methods, products, or apparatuses.

[0039] Figure 1 is one of the flow charts of a method for preparing polyhydroxyalkanoate of this exemplary embodiment, such as Figure 1As shown, an exemplary embodiment of the present disclosure provides a method for preparing a polyhydroxyalkanoate, comprising:

[0040] S1 obtains a cell suspension containing PHA;

[0041] S2 performs solid-liquid separation on the PHA cell suspension to collect a primary concentrate;

[0042] S3 deeply concentrates the primary concentrate and collects a secondary concentrate;

[0043] S4 uses a non-halogenated organic solvent to extract intracellular PHA from the secondary concentrate.

[0044] It is worth mentioning that the non-halogen organic solvent includes ethyl acetate, methyl acetate, ethyl propionate, dimethyl carbonate, petroleum ether, n-hexane, hexane and the like.

[0045] In an exemplary embodiment of the present disclosure, a cell suspension containing PHA is subjected to precipitation, photothermal evaporation, and solvent extraction treatment to separate PHA from other cytoplasm to obtain high-purity PHA, and the overall operation is simple.

[0046] Specifically, obtaining the PHA cell suspension comprises:

[0047] Collecting excess activated sludge from a municipal sewage treatment plant, wherein the excess activated sludge includes ordinary activated sludge, aerobic granular sludge or anaerobic granular sludge;

[0048] The remaining activated sludge is subjected to alkaline treatment to obtain an alkaline treatment solution;

[0049] The alkaline treatment solution is subjected to ultrasonic treatment to form a PHA-containing cell suspension.

[0050] Furthermore, the PHA cell suspension can also be extracted from industrial wastewater.

[0051] Specifically, the solid-liquid separation treatment is performed on the PHA cell suspension to collect the primary concentrate, which includes:

[0052] A solid-liquid separation device is used to perform solid-liquid separation on the PHA cell suspension, and the solid-liquid separation device includes a centrifuge, a sedimentation tank or a membrane separation device.

[0053] Figure 2 This is a flow chart of the second method for preparing polyhydroxyalkanoate of this exemplary embodiment. Figure 2 As shown, specifically, the first-level concentrate is deeply concentrated, and collecting the second-level concentrate comprises:

[0054] The primary concentrate is subjected to evaporation treatment to evaporate the water-soluble solvent in the primary concentrate to obtain a residual secondary concentrate.

[0055] Specifically, the extraction of intracellular PHA in the secondary concentrate using a non-halogen organic solvent includes: transmitting residual solar heat after photothermal evaporation of the primary concentrate to an extraction device to extract the intracellular PHA in the secondary concentrate.

[0056] This embodiment realizes the two-stage utilization of solar heat. Specifically, the heat from the high-quality heat source first enters the evaporator for deep concentration, and the low-quality heat coming out is used to supplement the heat for solvent extraction, thereby improving the extraction efficiency.

[0057] Furthermore, a third-level utilization can be carried out, in which light and heat are added again to separate PHA from the solvent, and the solvent can be recycled and reused.

[0058] Figure 3 This is a flow chart of a method for preparing polyhydroxyalkanoate of this exemplary embodiment. Figure 3 As shown, solar thermal energy is used to perform photothermal evaporation on the primary concentrate, so that the water-soluble solvent in the primary concentrate is evaporated to obtain the residual secondary concentrate.

[0059] This embodiment makes full use of recyclable solar energy, improves separation efficiency and reduces energy consumption.

[0060] Specifically, the alkaline treatment of the excess activated sludge to obtain an alkaline treatment solution comprises:

[0061] Add 35% NaOH to the remaining activated sludge, adjust the pH to 11, the temperature to 45°C, and keep stirring for 1-2 hours.

[0062] Specifically, the alkaline treatment solution is subjected to ultrasonic treatment to form a PHA cell suspension solution, comprising:

[0063] Stirring at a stirring speed of 500 to 1500 revolutions per minute for 3 to 8 hours;

[0064] Use an ultrasonic crushing device to perform ultrasonic treatment for 60 to 120 minutes while stirring at an output power of 200 to 800 W.

[0065] Specifically, the concentration of excess activated sludge in the urban sewage treatment plant is 5 to 15 g.L-1.

[0066] An exemplary embodiment of the present disclosure provides a polyhydroxyalkanoate, which is prepared by the polyhydroxyalkanoate preparation method.

[0067] Exemplary embodiments of the present disclosure provide a use of a polyhydroxyalkanoate in producing a cosmetic and / or pharmaceutical product.

[0068] The above are only preferred implementations of the present disclosure, and the protection scope of the present disclosure is not limited to the above embodiments. All technical solutions under the concept of the present disclosure belong to the protection scope of the present disclosure. It should be pointed out that for ordinary technicians in this technical field, some improvements and modifications without departing from the principle of the present disclosure should be regarded as the protection scope of the present disclosure.

Claims

1. A method for preparing polyhydroxyalkanoate, characterized in that: include: Obtaining a cell suspension containing PHA; Performing solid-liquid separation on the PHA cell suspension to collect a primary concentrate; Deeply concentrating the primary concentrate to collect a secondary concentrate; The intracellular PHA in the secondary concentrate was extracted using a non-halogen organic solvent.

2. The method for preparing polyhydroxyalkanoate according to claim 1, characterized in that: The obtaining of the PHA-containing cell suspension comprises: Collecting excess activated sludge from a municipal sewage treatment plant, wherein the excess activated sludge includes ordinary activated sludge, aerobic granular sludge or anaerobic granular sludge; The remaining activated sludge is subjected to alkaline treatment to obtain an alkaline treatment solution; Ultrasonic treatment is performed on the alkaline treatment solution to form a PHA cell suspension; The PHA cell suspension can also be extracted from industrial wastewater.

3. The method for preparing polyhydroxyalkanoate according to claim 1, characterized in that: The solid-liquid separation treatment is performed on the PHA cell suspension to collect the primary concentrate, which includes: A solid-liquid separation device is used to perform solid-liquid separation on the PHA cell suspension, and the solid-liquid separation device includes a centrifuge, a sedimentation tank or a membrane separation device.

4. The method for preparing polyhydroxyalkanoate according to claim 1, characterized in that: The first-stage concentrate is deeply concentrated, and collecting the second-stage concentrate comprises: The primary concentrate is subjected to photothermal evaporation treatment using solar thermal energy, so that the water-soluble solvent in the primary concentrate is evaporated to obtain the residual secondary concentrate.

5. The method for preparing polyhydroxyalkanoate according to claim 1, characterized in that: Extraction of intracellular PHAs from secondary concentrates using non-halogenated organic solvents includes: The remaining solar heat after photothermal evaporation of the primary concentrate is transmitted to the extraction equipment to extract the intracellular PHA in the secondary concentrate.

6. The method for preparing polyhydroxyalkanoate according to claim 2, characterized in that: The alkaline treatment of the residual activated sludge to obtain an alkaline treatment solution comprises: Add 35% NaOH to the remaining activated sludge, adjust the pH to 11, the temperature to 45°C, and keep stirring for 1-2 hours.

7. The method for preparing polyhydroxyalkanoate according to claim 2, characterized in that: The alkaline treatment solution is subjected to ultrasonic treatment to form a PHA cell suspension solution, comprising: Stirring at a stirring speed of 500 to 1500 revolutions per minute for 3 to 8 hours; Use an ultrasonic crushing device to perform ultrasonic treatment for 60 to 120 minutes while stirring at an output power of 200 to 800 W.

8. The method for preparing polyhydroxyalkanoate according to claim 2, characterized in that: The residual activated sludge concentration of the urban sewage treatment plant is 5 to 15 g.L-1.

9. Polyhydroxyalkanoate, characterized in that The polyhydroxyalkanoate is prepared by the polyhydroxyalkanoate preparation method according to any one of claims 1 to 8.

10. Use of the polyhydroxyalkanoate according to claim 9 in the production of cosmetics and / or pharmaceutical products.